Ellen Kullman

Ellen Kullman
Name	Ellen Kullman
Birth date	1956
Birth place	Boston
Alma mater	Tufts University; Massachusetts Institute of Technology
Occupation	Executive; director
Known for	Former CEO of DuPont

Ellen Kullman

Ellen Kullman is an American business executive and board director known for leading major multinational chemical industry and technology enterprises. She served as chief executive officer and chair of DuPont during a period of extensive portfolio transformation and later held senior roles and directorships across biotechnology, aerospace, defense, and financial services companies. Her tenure intersected with prominent corporate events and regulatory debates involving firms and institutions such as Dow Chemical Company, General Motors, ExxonMobil, Pfizer, and JP Morgan Chase.

Early life and education

Born in Boston and raised in the New England region, Kullman attended public schools before matriculating at Tufts University, where she earned a bachelor’s degree in mechanical engineering. She later completed graduate business coursework at the Massachusetts Institute of Technology Sloan School of Management, aligning her education with leading figures and institutions in engineering and management practice. During this period she engaged with student organizations and professional networks connected to companies like General Electric, Honeywell, IBM, and Raytheon that shaped early career pathways in the manufacturing and technology sectors.

Career

Kullman began her professional career in engineering and product development with roles at firms such as General Electric and Baker Hughes, moving into leadership positions that combined technical expertise with operational management. She joined DuPont in the 1980s, advancing through positions in research and development, supply chain, and commercial operations while interacting with units and partners including Dow Chemical Company, Monsanto, BASF, and 3M. Her career trajectory brought her into contact with regulatory bodies and industry associations like the U.S. Securities and Exchange Commission and the Department of Justice through mergers, licensing, and intellectual property matters involving companies such as Merck, Pfizer, and Eli Lilly.

Leadership at DuPont

As chief executive officer and later chair of DuPont, Kullman led strategic initiatives emphasizing portfolio reshaping, research commercialization, and global market expansion into regions served by ChemChina and Bayer. Her leadership coincided with large-scale transactions, divestitures, and a high-profile merger process with Dow Chemical Company that involved stakeholders including Carl Icahn, Elliott Management Corporation, and international regulators in European Union jurisdictions. During this phase she negotiated issues overlapping with product stewardship, environmental compliance, and litigation matters related to companies such as 3M and ExxonMobil. Kullman also prioritized investment in advanced materials and life sciences businesses, aligning DuPont’s portfolio with customers such as Boeing, Ford Motor Company, Procter & Gamble, and Johnson & Johnson.

Her tenure was marked by public scrutiny and policy discussion around corporate restructuring, where institutions such as The New York Stock Exchange, NASDAQ, and academic commentators from Harvard Business School and Wharton School analyzed the governance, risk, and shareholder outcomes of the DuPont–Dow negotiations. Executive compensation and succession planning during her departure became topics of reporting by outlets like The Wall Street Journal and The New York Times and subject to review by proxy advisory firms including Institutional Shareholder Services.

Later roles and board memberships

After leaving DuPont, Kullman served as chief executive officer of Carbon Inc., a 3D printing and materials company, engaging with industrial partners and investors including Sequoia Capital, Silver Lake Partners, and technology customers such as Nike and Caterpillar. She has held board directorships at prominent organizations including General Motors (as lead independent director), ExxonMobil, Pfizer, JP Morgan Chase, and Carbon3D. Her board service placed her in governance dialogues about climate change–related strategy, supply chain resilience, cyber risk, and regulatory compliance with entities like the Environmental Protection Agency and international standards bodies. Kullman’s governance roles also connected her to philanthropic and research institutions such as Massachusetts General Hospital, Broad Institute, and university advisory boards at Tufts University and MIT.

Awards and recognition

Kullman has received industry and civic honors from organizations such as the National Academy of Engineering affiliates, Fortune magazine’s lists of influential business leaders, and awards presented by The Business Council and trade groups including the Society of Chemical Industry. She has been recognized by publications like Forbes, Bloomberg Businessweek, and Harvard Business Review for leadership in innovation and corporate transformation. Professional societies including the American Institute of Chemical Engineers and the National Association of Corporate Directors have cited her for contributions to board governance and executive management.

Personal life and philanthropy

Kullman resides in the Boston metropolitan area and participates in philanthropic activities supporting scientific research, healthcare, and education. She has been active with charitable organizations and trusteeships at institutions including Tufts University, Massachusetts General Hospital, and research consortia connected to biomedical research. Her philanthropic interests have intersected with initiatives addressing workforce development and STEM outreach programs involving partnerships with companies such as Microsoft, Google, and nonprofit groups like Girls Who Code and the American Red Cross.

Category:American chief executives Category:Businesspeople from Boston